• Publications
  • Influence
Reovirus therapy of tumors with activated Ras pathway.
Human reovirus requires an activated Ras signaling pathway for infection of cultured cells. To investigate whether this property can be exploited for cancer therapy, severe combined immune deficientExpand
  • 668
  • 12
Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.
Glioblastoma patients are immunosuppressed, yet glioblastomas are highly infiltrated by monocytes/macrophages. Myeloid-derived suppressor cells (MDSC; immunosuppressive myeloid cells includingExpand
  • 185
  • 11
Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells.
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) regulate proteolysis of the extracellular matrix and other extracellular proteins, including growth factors andExpand
  • 182
  • 7
Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps.
Neutrophils mediate bacterial clearance through various mechanisms, including the release of mesh-like DNA structures or neutrophil extracellular traps (NETs) that capture bacteria. AlthoughExpand
  • 234
  • 6
Reovirus as an oncolytic agent against experimental human malignant gliomas.
BACKGROUND Reovirus is a naturally occurring oncolytic virus that usurps activated Ras-signaling pathways of tumor cells for its replication. Ras pathways are activated in most malignant gliomas viaExpand
  • 210
  • 6
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production
Oncolytic viruses constitute a promising therapy against malignant gliomas (MGs). However, virus-induced type I IFN greatly limits its clinical application. The kinase mammalian target of rapamycinExpand
  • 107
  • 6
Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil.
The concept of oncolytic viral therapy has a century-old history, but only within the last 20 years have oncolytic viruses been considered for the treatment of brain cancers. Viruses such as herpes,Expand
  • 54
  • 5
Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas.
Malignant gliomas maintain a poor prognosis and survival rate due to their marked local invasive growth and neovascularization. Matrix metalloproteinases (MMPs) have been implicated in gliomaExpand
  • 91
  • 4
Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy.
Malignant gliomas (MGs) are deadly brain tumors with a median survival after resection, radiotherapy and chemotherapy of only 12 months. The natural immunosuppressive state of MG patients and theExpand
  • 30
  • 3
Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
BACKGROUND An ideal virus for the treatment of cancer should have effective delivery into multiple sites within the tumor, evade immune responses, produce rapid viral replication, spread within theExpand
  • 93
  • 2